17 Quotes by Mark Landy

While it could be a knock-out blow, at what point are we overpaying? I think we could be getting close to that point based on the cardiac rhythm business.

We expect prices to continue to decline. Leverage helps on the way up and it hurts on the day down. Boston Scientific recognizes it and that's why they want Guidant.

This offer is superior. This offer promises a higher price, stock with better appreciation potential, commitments to do what it takes to avoid antitrust concerns, and a firm timeline.

They are buying a crown jewel and they are getting it at a reasonable valuation.

You can't just sit back on your laurels. You have to constantly innovate.

This is a very simple integration. It should not be difficult.

It they found somebody who could clean up ship a little, it sends a message.

I don't see material upside or downside (for Boston Scientific shares) for the next 12 months.